I PD-1
CD28 family of receptors, CTLA-4 cytotoxic T Lymphocyte-associated antigen 4, ICOS inducible costimulator, and B- and T-lymphocyte attenuator.
Immunohistochemistry, Technical component (TC) available
This assay utilizes the NAT105 mouse monoclonal antibody for immunohistochenical detection of the immune regulatory molecule programmed death-1 (PD-1).
2 days
Paraffin embedded tissue block
3 slides (3-5 uM) per marker on adhesion glass
Ship ambient. Protect from extreme temperature with ice pack. Separate ice pack from specimen.
Improper specimen labeling; Insufficient sample; Inadequate fixation and/or processing
Quantitative in Tumor Infiltrating Lymphocytes (TILs): Cut off POSITIVE in =/>1% of tumor infiltrating lymphocytes (TILs); NEGATIVE (no reactivity in tumor infiltrating lymphocytes, <1%)
Qualitative PD-1 immunoreactivity is demonstrated in x% of lymphocytes
Detection of PD-1 protein expression by immunohistochemistry has utility in both hematopathology diagnostics and in cancer biology. The programmed death-1 (PD-1) protein is expressed by follicular helper T-cells, and is useful in the diagnosis of hematolymphoid malignancies such as angioimmunoblastic T-cell lymphoma (AITL). In addition, clinical evidence suggests that IHC staining of the PD-1/PD-L1 pathway may have prognostic and/or therapeutic significance in some cancer patients.